相关实验视频
Updated: Jun 17, 2025

06:22
Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
Published on: November 29, 2024
558
在2型糖尿病中综合多重风险因素控制以减轻心力衰竭风险:来自前性队列研究的见解
Ze-Gui Huang1, Jing-Wei Gao1, Zhi-Teng Chen1
1Department of Cardiology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
Diabetes care
|August 13, 2024
概括
综合性风险因素控制显著降低了2型糖尿病 (T2D) 中心力衰竭 (HF) 的风险. 最佳的管理可能会延长T2D患者的无HF生存时间.
科学领域:
- 心脏病学 心脏病学
- 内分泌学 在内分泌学.
- 公共卫生 公共卫生
背景情况:
- 2型糖尿病 (T2D) 是心力衰竭 (HF) 的重要危险因素.
- 对T2D患者来说,有效管理心血管风险因素至关重要.
- 之前的研究强调了T2D和HF发病率增加之间的联系.
研究的目的:
- 评估综合风险因素控制对心力衰竭风险的影响.
- 评估风险因素管理对T2D患者无HF生存时间的影响.
主要方法:
- 来自英国生物库的1,949名T2D患者和47,796名对照者的前性研究.
- 对主要心血管风险因素的评估:血压,BMI,LDL胆固醇,HbA1c,功能,吸烟,饮食,身体活动.
- 使用了考克斯的比例危险模型和受限平均存活时间分析.
主要成果:
- 每一个额外的受控风险因素,都将HF风险降低19%.
- 最佳控制六个风险因素可以将HF风险降低67% (HR 0.33).
- 过度的T2DHF风险被减弱到控制水平,具有最佳的风险因素管理.
结论:
- 综合性风险因素管理与T2D中的HF风险相反相关.
- 在T2D患者中,最佳的风险因素控制可以显著延长无HF生存时间.
- 体重指数 (BMI) 成为HF的主要可归因风险因素.
相关概念视频
Diabetes: Management and Pharmacotherapy
246
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
246
Diabetes Mellitus: Type 2 and Gestational
2.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.3K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
405
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
405
Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Diabetes Mellitus: Overview and Type I Subtype
2.5K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.5K
Heart Failure Drugs: β-Blockers
324
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
324

